

-

-

:

:

-

, 2014.

1.		4
	1.1.	4
	1.2.	6
	1.3.	9
	1.4.	10
	1.5.	15
	1.6.	16
	1.7.	19
	1.8.	22
2.		23
3.		24
4.		25
5.		29
6.		31
7.		72
8.		80
9.		81

LT -

ST -

-

-

-

-

-

-

-

SVR -

EVR -

PH -

F-

1.

(.)
1300-1800 2,5% .
(x), .
, . 250
72-78% , 3/4 .
, 300 .
,
(1).

, .
1989. ,
, -
() ()
, - , - .

1.1.

() .
170-200.000.000 . 3-
4.000.000 250.000 .
75.000-100.000.
. 1%,
1,2%, 0,68-4,9%, 1,8%,
2,5-4,9%, 1-12% 6-28% (2, 3, 4).

-
-
-
- (,)
-
- ,
- 30% (2, 3, 4, 5, 6, 7, 8).

, 60-90% .
65%, 90% 5 .

, , (9) .

—

(60-80%).

2.1% .

1:103000 .

12 .

(polimerasa chein reaction) , " "

16 4

2 42 , 0.2-9400

7.5 10^{-3} / / 3' 5' ()


(NS1) C 22 kD, 1 2 gp33, 2 gp70.

NS2, NS3, NS4 NS5

NS2 NS4 , NS3 - , NS5

(6, 7, 13, 14, 15).

1.



(10^{12}),

(16, 17).

(cor) NS3 NS5 , 6
1 6 80 .
2, NS5 3' UTR ,
70%.

, , (80%) (18, 19, 20).

(1 , 1 , 2 , 2) , (4 , 5 , 6)
(15, 21).


1 1
2 3.
1 ,
4. 5

, 1 , 2 2 , 3 .
6.
1 3 (21, 22, 23, 24).

2.



1.3.



(+) (-) - , "template" (+) -
.
(+) -
.

“fr msift”
,
(Alternate Reading Frame Protein –ARFP).

10 ,

1.4.

15-150 (50)
() .

10-15% .

(40-50 /).


90%

5-15%

(LT)

(ST) ,
2-8 ,
1-2 . -
, 1-3 .
-
.
20% .
70-80% .
() 6
() (25, 26).

3.



1-2%

(25, 26, 27, 28).

20

20-30%

30-40%

50%

(6, 14, 29, 30, 31).

:

1. :

-
-
-
- Non- Hodgkin

2. :

- Porphiria cutanea tarda
- Lichen planus
-

3. :

-
-

4. :

- -
-

5. :

- Sialoadenitis

6. :

-
- Uveitis

7. :

-
- Poliarteritis nodosa

8. :

- Mialgia
-
- Artritis

9.

-

-

1.5.

```
                                )
                                (" interface hepatitis"),
                                )
                                ,
                                , )
                                (32), )
                                )
                                :
                                ,
                                ,
                                "interface hepatitisom",
                                ,
                                : )
                                , )
                                ) Mallor-
                                .
                                ,
                                ) )
                                .
                                ,
                                .
                                .
```

1.6.

: c c22-3, NS3, NS4 NS5.

: RIBA, Western blot Inno-Lipa .

1-2

5*

Knodell-

0 3,

F F0 F6

.1, 2, 3.

1.

HAI	
1-3	
4-8	
9-12	
13-18	

2.

	0
	1
	2
-	3
-	4
	5
	6

3. Knodell- v
(HAI)

		0
		1
		2
/		3
		4
. Interface		
		0
		1
/		2
		3
		4
.		
		0
	10x	1
2-4	10x	2
5-10	10x	3
10	10x	4
.		
		0
		1
3		2
3		3
3+ Bridging		4
3+ Multiply bridging		5
Panacinarne multiple		6
	<u>HAI</u>	<u>18</u>

1/50.000 . 2,0 11 ,
,
(F1 F2 F3 F4). (32, 33).

1.7.

,
,
.
:
-
-
-
-
-
.
.
,
.
,
,
,
.

85%

12-

2

1. 3MU, 3 12 ().

2. 5-10MU INF ,

3 4-6 .
) INF 5 MU 4 , 5 MU 3 20

) INF 10 MU (3-6)

(
) 95% (34, 35).

-2 (Pegasys)

-2

(,
) .

1, 4, 5 6, Pegasyssa 180
1000 1200 ()
2 3 Pegasyssa 180
800 .
. 1, 4, 5 6
48 . 1 4
() ,
24 . 2 3 24
, 16 (12, 36, 37, 38, 39, 40, 41).
(SVO),
. (<50 IU/ml) 24
. 12 (42).
. : , , ,
, , . (18, 43,
44).
, 12
. 12 log (42, 45).
, 100%

(flu-like symptoms) . (46, 47).

(48, 49, 50) . elapravir boceprevir

1.8.

2.

- ,
- - ,
- ()
- ,
- .

3.

- :
1 3
- , 4;
30-50
- ;
- , ,
;
- ;
- ;
- ,
- ;
- .

4.

.) 64 (, ,
2007-2010.
:
(
)
,
(
, ,
)
,
(
- 2
) 180
. 1 4
1000 1200 800
2 3.

) , , ,
, ,
, ,
" " ,
:
- : , , , ,
;
- : , :
- ;
- : , , , ,
, , , ;
- ;
:
- (LT),
6
- -
-
-
, , , (,
, , , .)

“staging” METAVIR skorom
: F-0 , F-1 , F-2 -
, F-3 , F-4 .

a
12 (), (24 48
) 6 .

: 800.000 k/ml ((400.000 IU/ml)
800.000 k/ml ((400.000 IU/ml). 12

-EVR.

12
(48 1 24 2 3)

- 6

12

)

“ “

(Polymerase Chain Reaction, Hepatitis C Virus, Ribonucleic Acid).

: Cobas Amplicor HCV Test version 2.0 (Roche Diagnostics,
Menheim), o : 50 IU/ml.

: Cobas Amplicor HCV Monitor test version 2.0 (Roche
Diagnostics, Menheim), o : 600 IU/ml.

: Linear Array HCV genotyping test (Roche Diagnostics).

5.

(\bar{X}_{sr}), (SD), (Min),
(Max) (%).

t Man-Vitni (Mann-Whitney) U ,

(One-way ANOVA) (post hoc)

(Tukey)

Hancelovim Hi (Mantel-Haenszel Chi square test)
(Fisher exact test),

(odds ratio - OR) 95%

(Repeated Measures
ANOVA) Greenhouse- Geisser

(p<0,05).


5%

Exsel

Microsoft Office 2003 .
SPSS 10.0 Statcalc EPI-INFO
6.


6.

1.



64 , 22 (34%) , 42 (66%)
20 (31,25%) 30
39 , 40 49 17 (26,56%) 50 59
16 (25,0%) 20 29 3 (4,69%)
, 60 69 6 (9,38%), 70
2 (3,13%) .

2.



(H_0 : $\chi^2=16,78$ $p=0,005$; $p<0,01$).


, 19 (45,2%) 30 39
 , 50 59 10 (23,8%) 40 49
 7 (16,7%) 20 29 3 (7,1%)
 60 69 2 (4,8%), 70 (2,4%)
 , 10 (45,5%)
 40 49 , 50 59 6 (27,3%) 60
 69 4 (18,2%) 30 39 70
 (4,5%) , 30 .

4.

			(n=64)
	(n=42)	(n=22)	
Xsr	43,17	52,09	46,23
SD	11,95	8,94	11,74
Min	20,00	37,00	20,00
Max	78,00	75,00	78,00

20 78 . 46,23±11,74 ,
 20, 78 . 43,17±11,95 ,
 (Studentov t test : t=3,36 p=0,001; p<0,01) 52,09±8,94 ,
 37 75 .
 , 28 (43,8%),
 , 18 (28,1%) , 11 (17,2%)
 , 6 (9,4%) , (1,6%)
 .
 (38,10:9,1%; Fišerov test: p=0,019;
 p<0,05),
 (36,40:7,1%; Fišerov test: p=0,006; p<0,01).

3.




5.

				o (n=64)
		(n=42)	(n=22)	
1		24	15	39
		57,1%	68,2%	60,9%
3		17	6	23
		40,5%	27,3%	35,9%
4		1	1	2
		2,4%	4,5%	3,1%

1 39 (60,9%) , 3 23 (35,9%),
 4 2 (3,1%) . Хи квадрат Фишеров

($p > 0,05$).

4.



6.

				(n=58)
		(n=40)	(n=18)	
F0		3	2	5
		7,5%	11,1%	8,6%
F1		16	2	18
		40,0%	11,2%	51,2%
F2		15	9	24
		37,5%	50,0%	41,4%
F3		2	2	4
		5,0%	11,1%	6,9%
F4		4	3	7
		10,0%	16,7%	12,1%

(41,4%)

(51,2%).

7 (12,1%)

5 (8,6%)

. Hi kvadrat Fišerov

(p>0,05)

7. ALT (U/L),

	(n=42)	(n=22)	(n=64)
Xsr	76,13	88,93	80,53
SD	35,77	38,63	36,98
Min	38,70	48,70	38,70
Max	179,30	175,50	179,30

ALT 80,53±36,98 U/L,
 38,70 179,30 U/L. ALT 76,13±35,77 U/L.
 ALT (88,93±38,63 U/L), Man-
 Vitni U ALT

(p>0,05).

, 50 (79,4%) , 33
 (80,5%) 17 (77,3%) .

3 (4,8%)

10 (15,9%)


, 5 (12,2%)

5 (22,7%)

Hi kvadrat Fišerov

(p>0,05).

5.



8.

($\bar{X}_{sr} \pm SD$)

	(n=42)	(n=22)	(n=64)
(n=64)	6.363.067±11.020.000	3.425.996±3.240.923	5.353.449±9.193.775
12 (n=64)	34.210±142.321	406.292±1.253.578	162.113±754.141
24 (n=23)	29.750±93.773	95.890±234.881	47.004±140.767
48 (n=39)	35.274±155.906	22.291±85.707	30.281±132.133
6 (n=63)	789.767±2.733.865	151.043±473.159	566.721±2.234.276

162 . 5,353 . , 12 , ,
 23 3 , 24 ,
 47 , 39
 1 4 , 48 ,
 30 . , 6
 , 567 .

9 .


		F	p
		1,70	0,197
		13,05	<0,001
	*	1,53	0,222

(F=1,70 p=0,179; p>0,05).

(F=13,05 p<0,001),

(F=1,53 p=0,222; p>0,05).

6.



800000 49 (76,6%)

800000 4,7% 12

800000 23 3 24

39 1 4 48

800000 4

(6,3%)

800000

(Hi kvadrat Fišerov test: $p > 0,05$).

10 .

	800000k/ml		8	7	15
			19,0%	31,8%	23,4%
	800000k/ml		34	15	49
			81,0%	68,2%	76,6%
12	800000k/ml		41	20	61
			97,6%	90,9%	95,3%
	800000k/ml		1	2	3
			2,4%	9,1%	4,7%
24	800000k/ml		17	6	23
			100,0%	100,0%	100,0%
	800000k/ml		0	0	0
			0,0%	0,0%	0,0%
48	800000k/ml		24	15	39
			100,0%	100,0%	100,0%
	800000k/ml		0	0	0
			0,0%	0,0%	0,0%
6	800000k/ml		38	21	59
			92,7%	95,5%	93,7%
	800000k/ml		3	1	4
			7,3%	4,5%	6,3%

66,7% , 30 39 20 29 70,0% .
 , 40 49
 11,8% , 50

. Hi kvadrat

($\chi^2=31,20$

$p<0,001$).


		50	59	60	69	66,7%
				25,0%		40
						49
						40
			70			

. Hi kvadrat

($\chi^2=16,20$ $p=0,006$; $p<0,01$).

($p>0,05$).


7.



1 (83,3%) 20 29 (66,7%). 50 59 (87,5%), 60 69 3

(50,0%), 40 49 (47,1%), 30 39 (55,0%), 70
 30 39 (5,0%), 50 59 (6,3%).
 Хи квадрат Фишеров (p>0,05).

8.



11.

		()						n=58
		20 o 29 (n=3)	30 o 39 (n=20)	40 do 49 (n=15)	50 59 (n=12)	60 69 (n=6)	70 (n=2)	
F		2	1	1	0	1	0	5
		66,7%	5,0%	6,7%	0,0%	16,7%	0,0%	8,6%
F1		1	9	3	4	0	1	18
		33,3%	45,0%	21,0%	33,3%	0,0%	50,0%	31,0%
F2		0	7	9	5	2	1	24
		0,0%	35,0%	60,0%	41,7%	33,3%	50,0%	41,4%
F3		0	3	1	0	0	0	4
		0,0%	15,0%	6,7%	0,0%	0,0%	0,0%	6,9%
F4		0	0	1	3	3	0	7
		0,0%	0,0%	6,7%	25,0%	50,0%	0,0%	12,1%

20 29
(66,7%). 30 39
(35,0%), 40
49 (60,0%) 50 59 (41,7%). 60 69
(50,0%), 70

(50,0%). Hi kvadrat

PH

($\chi^2=38,67$ p=0,040; p<0,05).

12 .

ALT (U/L),

	()					
	20 29 (n=3)	30 39 (n=20)	40 49 (n=15)	50 59 (n=12)	60 69 (n=6)	70 (n=2)
Xsr	57,70	72,45	83,75	83,43	98,87	89,95
SD	16,72	29,40	35,60	42,82	56,44	10,11
Min	39,00	38,70	49,70	38,70	41,60	82,80
Max	71,20	166,90	179,30	175,50	159,60	97,10

ALT (98,87±56,44 U/L) (89,95±10,11 U/L),
 (72,45±29,40 U/L), (57,70±16,72 U/L),
 Turkijev (p>0,05).

13.


		()						(n=63)
		20 o 29 (n=3)	30 o 39 (n=19)	40 o 49 (n=17)	50 o 59 (n=16)	60 o 69 (n=6)	70 (n=2)	
SVR		3	17	13	11	5	1	50
		100,0%	89,5%	76,5%	68,8%	83,3%	50,0%	79,4%
R		0	1	0	2	0	0	3
		0,0%	5,3%	0,0%	12,5%	0,0%	0,0%	4,8%
NR		0	1	4	3	1	1	10
		0,0%	5,3%	23,5%	18,8%	16,7%	50,0%	15,9%

20 29 (100,0%) 30 39 (89,5%),
 70 (50,0%), 50 59
 (68,8%).
 2 (12,5%)
 50 59 (5,3%)
 30 39 .
 70 (50,0%) 40 49 (23,5%).

Hi kvadrat Fišerov

(p>0,05).

9.




14.

	F	p
	0,75	0,586
*	0,91	0,486

(F=0,75 p=0,586; p>0,05).

(F=0,91 p=0,486; p>0,05).

10.



800000

29

(100,0%),

40 49 (94,1%). 12

40 49 (5,9%), 50 59 (6,3%) 60 69 (16,7%).

800000

2 (12,5%) 50 59

30 39 (5,3%) 60 69 (16,7%).

800000

47

(Hi

kvadrat Fišerov : $p > 0,05$).

15.

			()					70	
			20 o 29	30 o 39	40 o 49	50 o 59	60 o 69		
	800000k/ml		0	6	1	6	2	0	15
			0,0%	30,0%	5,9%	37,5%	33,3%	0,0%	23,4%
	800000k/ml		3	14	16	10	4	2	49
			100,0%	70,0%	94,1%	62,5%	66,7%	100,0%	76,6%
12	800000k/ml		3	20	16	15	5	2	61
			100,0%	100,0%	94,1%	93,8%	83,3%	100,0%	95,3%
	800000k/		0	0	1	1	1	0	3
			0,0%	0,0%	5,9%	6,3%	16,7%	0,0%	4,7%
24	800000 /ml		1	11	8	1	1	1	23
			100,0%	100,0%	100,0%	100,0%	100,0%	100,0%	100,0%
	800000k/ml		0	0	0	0	0	0	0
			0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
48	800000k/		2	8	8	15	5	1	39
			100,0%	100,0%	100,0%	100,0%	100,0%	100,0%	100,0%
	800000 /ml		0	0	0	0	0	0	0
			0,0%	0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
6	800000k/ml		3	18	17	14	5	2	59
			100,0%	94,7%	100,0%	87,5%	83,3%	100,0%	93,7%
	800000k/ml		0	1	0	2	1	0	4
			0,0%	5,3%	0,0%	12,5%	16,7%	0,0%	6,3%

16.

()

	1	3	4
	(n=39)	(n=23)	(n=2)
Xsr	48,31	42,57	48,00
SD	11,86	10,90	15,56
Min	20,00	28,00	37,00
Max	78,00	75,00	59,00

1 48,31±11,86 ,
 3 42,57±10,90 , 4
 48,00±15,56 . Tukijev
 (p>0,05).


17.

		1	3	4	n=64
		(n=39)	(n=23)	(n=2)	
		18	9	1	28
	%	46,2%	39,1%	50,0%	43,8%
		6	0	0	6
		15,4%	0,0%	0,0%	9,4%
		8	9	1	18
		20,5%	39,1%	50,0%	28,1%
		0	1	0	1
		0,0%	4,3%	0,0%	1,6%
		7	4	0	11
		17,9%	17,4%	0,0%	17,2%

Генотип	Трансфузија	Сексуални пут	IV наркоманија	Дијализа	Непознат
Генотип 1	1, 39,1%	3, 50,0%	4, 61,5%	1, 16,7%	1, 16,7%
Генотип 3	3, 17,4%	4, 21,1%	1, 5,3%	1, 5,3%	1, 5,3%
Генотип 4	1, 17,9%	3, 50,0%	4, 61,5%	1, 16,7%	1, 16,7%

(Hi kvadrat Fišerov : $p > 0,05$).

12.



18. ALT (U/L)

	1 (n=33)	3 (n=23)	4 (n=2)
Xsr	78,52	85,20	65,80
SD	39,05	35,01	12,30
Min	38,70	42,70	57,10
Max	179,30	166,90	74,50

ALT 1 78,52±39,05 U/L,
 3 85,20±35,01 U/L, 4
 65,80±12,30 U/L. Tukijev
 (p>0,05).

19.

					n=58
		1 (n=33)	3 (n=23)	4 (n=2)	
F0		3	2	0	5
		9,1%	8,7%	0,0%	8,6%
F1		11	6	1	18
		33,4%	26,1%	50,0%	31,0%
F2		14	10	0	24
		42,4%	43,5%	0,0%	41,4%
F3		0	3	1	4
		0,0%	13,0%	50,0%	6,9%
F4		5	2	0	7
		15,2%	8,7%	0,0%	12,1%

					9,1%
1	8,7%		3.		
33,4%		3	50,0%		4.
		42,4%		1	43,5%
3.			13,0%		3
50,0%		4,	15,2%		1 8,7%
		3.			

(Hi kvadrat Fišerov : p>0,05).

20 .


					n=63
		1 (n=38)	3 (n=23)	4 (n=2)	
SVR		30	18	2	50
		78,9%	78,3%	100,0%	79,4%
R		1	2	0	3
		2,6%	8,7%	0,0%	4,8%
NR		7	3	0	10
		18,4%	13,0%	0,0%	15,9%

		(SVR)		78,9%	
1, 78,3%		3		(100,0%)	4.
(R)					(2,6%)
	1	(8,7%)		3.	
(NR)		7 (18,4%)		1	(13,0%)
	3.				

Hi kvadrat Fišerov

($p > 0,05$).

14.



21.

			1	3	4	
	800000k/ml		9	6	0	15
			23,1%	26,1%	0,0%	23,4%
	800000k/ml		30	17	2	49
			76,9%	73,9%	100,0%	76,6%
12	800000k/ml		36	23	2	61
			92,3%	100,0%	100,0%	95,3%
	800000k/ml		3	0	0	3
			7,7%	0,0%	0,0%	4,7%
24	800000k/ml		0	23	0	23
			0,0%	100,0%	0,0%	100,0%
	Preko 800000k/ml		0	0	0	0
			0,0%	0,0%	0,0%	0,0%
48	800000k/ml		37	0	2	39
			100,0%	0,0%	100,0%	100,0%
	800000k/ml		0	0	0	0
			0,0%	0,0%	0,0%	0,0%
6	800000k/ml		36	21	2	59
			94,7%	91,3%	100,0%	93,7%
	800000k/ml		2	2	0	4
			5,3%	8,7%	0,0%	6,3%

800000 , ,
76,9% 1, 73,9% 3
(100,0%) 4. 12
37,7%) 1. 800000
, , .
800000 2 (5,3%)

1 2 (8,7%)

3.

800000

(Hi kvadrat

Fišerov : $p > 0,05$).

22 .


	F	p
	1,15	0,323
*	0,89	0,424

($F=1,15$ $p=0,323$; $p > 0,05$).

($F=0,89$ $p=0,424$;

$p > 0,05$).

15.



23 .

		(n=28)	(n=6)	(n=18)	(n=1)	(n=11)
F0		3	...	1	0	1
		10,7%	...	5,6%	0,0%	9,1%
F1		6	...	9	1	2
		21,5%	...	50,0%	100,0%	18,2%
F2		12	...	6	0	6
		42,9%	...	33,3%	0,0%	54,5%
F3		1	...	2	0	1
		3,6%	...	11,1%	0,0%	9,1%
F4		6	...	0	0	1
		21,4%	...	0,0%	0,0%	9,1%

3 (10,7%)

(5,6%)

(9,1%).

6

(21,5%),

1

(100,0%)

2

(18,2%)

9 (50,0%)

12 (42,9%)

, 6 (33,3%)

6 (54,5%)

1 (3,6%)

, 2

(11,1%)

1 (9,1%)

6 (21,4%)

1 (9,1%)

(Hi kvadrat Fišerov : $p > 0,05$).

24. ()


	(n=28)	(n=6)	(n=18)	(n=1)	(n=11)
Xsr	48,36	50,67	35,44	48,00	55,91
SD	12,83	1,86	4,71		6,91
Min	20,00	48,00	27,00	48,00	45,00
Max	78,00	53,00	46,00	48,00	65,00

($35,44 \pm 4,71$) ($48,36 \pm 12,83$;
 ANOVA Tukijev : $p < 0,001$), ($50,67 \pm 1,86$; $p = 0,006$; $p < 0,01$)
 ($55,91 \pm 6,91$; $p < 0,001$).

25.

	F	p
	0,72	0,580
	*	0,795

17.



(F=0,72 p=0,580; p>0,05).

(F=0,44 p=0,795; p>0,05).

26.

	800000k/ml		6	2	4	0	3
			21,4%	33,3%	22,2%	0,0%	27,3%
	800000k/ml		22	4	14	1	8
			78,6%	66,7%	77,8%	100,0%	72,7%
12	800000k/ml		26	5	18	1	11
			92,9%	83,3%	100,0%	100,0%	100,0%
	800000k/ml		2	1	0	0	0
			7,1%	16,7%	0,0%	0,0%	0,0%
24	800000k/ml		9	0	9	1	4
			100,0%	0,0%	100,0%	100,0%	100,0%
	800000k/ml		0	0	0	0	0
			0,0%	0,0%	0,0%	0,0%	0,0%
48	800000k/ml		17	6	9	0	7
			100,0%	100,0%	100,0%	0,0%	100,0%
	800000k/ml		0	0	0	0	0
			0,0%	0,0%	0,0%	0,0%	0,0%
6	800000k/ml		23	6	18	1	11
			85,2%	100,0%	100,0%	100,0%	100,0%
	800000k/ml		4	0	0	0	0
			14,8%	0,0%	0,0%	0,0%	0,0%

800000 , , 22
 (78,6%) , 4 (66,7%)
 , 14 (77,8%) , (100,0%)
 8 (72,7%) . 12
 , , 2 (7,1%)
 59

(16,7%)

800000

800000

4 (14,8%)

800000

(Hi kvadrat

Fišerov : p>0,05).

27 .

ALT

	(n=28)	(n=6)	(n=18)	(n=1)	(n=11)
Xsr	90,21	89,72	67,73	49,70	74,62
SD	41,43	52,64	22,28		31,81
Min	44,70	38,70	38,70	49,70	41,60
Max	179,30	175,50	111,00	49,70	139,00

ALT

(90,21±41,43 U/L)

(89,72±52,64 U/L),

(49,70 U/L)

(67,73±22,28 U/L),

Tukijev

(p>0,05).

28 .

		(n=27)	(n=6)	(n=18)	(n=1)	(n=11)
SVR		19	4	17	0	10
		70,4%	66,7%	94,4%	0,0%	90,9%
R		3	0	0	0	0
		11,1%	0,0%	0,0%	0,0%	0,0%
NR		5	2	1	1	1
		18,5%	33,3%	5,6%	100,0%	9,1%

19 (70,4%)
, 4 (66,7%) , 17 (94,4%)
(5,6%) 10 (90,9%)
3 (11,1%)
5
(18,5%) , 2 (33,3%)
, (5,6%) , (100,0%)
(9,1%)

Hi kvadrat Fišerov

($p > 0,05$).

29 .

()

PH

	F0 (n=5)	F1 (n=18)	F2 (n=24)	F3 (n=4)	F4 (n=7)
Xsr	37,40	43,21	47,21	38,25	56,71
SD	17,02	12,55	10,59	4,99	6,55
Min	20,00	28,5	32,00	33,00	46,00
Max	64,00	68,00	75,00	45,00	63,00

(37,40±17,02:56,71±6,55 ; ANOVA Tukijev : p=0,048;
p<0,05).

(p>0,05).

30 .

ALT (U/L)

PH

	(n=5)	(n=18)	(n=24)	(n=4)	(n=7)
Xsr	77,62	67,48	65,12	106,70	147,76
SD	32,60	19,49	21,70	41,16	19,02
Min	48,70	44,35	38,70	74,50	121,80
Max	133,50	100,20	121,30	166,90	179,30

ALT 147,76±19,02 U/L
(77,62±32,60 U/L; ANOVA Tukijev : p<0,001),

(67,48±19,49 U/L; p<0,001)
 p<0,001).

(65,12±21,70 U/L;

ALT 106,70±41,16 U/L
 (r=0,039; p<0,05)
 (p=0,020; p<0,05).

31 .

PH

		(n=4)	(n=18)	(n=24)	(n=4)	(n=7)
SVR		4	14	20	4	4
		100,0%	79,2	83,3%	100,0%	57,1%
R		0	0	1	0	2
		0,0%	0,0%	4,2%	0,0%	28,6%
NR		0	4	3	0	1
		0,0%	20,8%	12,5%	0,0%	14,3%

, 14 (79,2%)
 4 (57,1%)

, 20 (83,3%)

(4,2%)

2 (28,6%)

(20,8%)

, 3 (12,5%)

(14,3%)

Hi kvadrat Fišerov

($p > 0,05$).


32 .

PH

		F	p
	PH	2,82	0,026
	*PH	3,11	0,012

($F=2,82$ $p=0,026$; $p < 0,05$).

($F=3,11$ $p=0,012$; $p < 0,05$).



			F0	F1	F2	F3	F4	n
1	SVR		2	9	12	0	3	26
			6,3%	28,2%	37,5%	0,0%	9,4%	81,3%
	R		0	0	0	0	1	1
			0,0%	0,0%	0,0%	0,0%	3,1%	3,1%
	NR		0	2	2	0	1	5
			0,0%	6,3%	6,3%	0,0%	3,1%	15,6%
		2	11	14	0	5	32	
		6,3%	34,4%	43,8%	0,0%	15,6%	100,0%	
3	SVR		2	4	8	3	1	18
			8,7%	17,3%	34,8%	13,0%	4,3%	78,3%
	R		0	0	1	0	1	2
			0,0%	0,0%	4,3%	0,0%	4,3%	8,7%
	NR		0	2	1	0	0	3
			0,0%	8,6%	4,3%	0,0%	0,0%	13,0%
		2	6	10	3	2	23	
		8,7%	26,1%	43,5%	13,0%	8,7%	100,0%	
4	SVR		0	1	0	1	0	2
			0,0%	50,0%	0,0%	50,0%	0,0%	100,0%
	R		0	0	0	0	0	0
			0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
	NR		0	0	0	0	0	0
			0,0%	0,0%	0,0%	0,0%	0,0%	0,0%
		0	1	0	1	0	2	
		0,0%	50,0%	0,0%	50,0%	0,0%	100,0%	

32	1,		
26 (81,3%)	,		(12; 37,5%)
(9; 28,2%).	3 (9,4%)	,	
2 (6,3%)	.	(3,1%)	1
	,		.
		5 (15,6%)	1,
2 (6,3%)		, 1 (3,1%)	.
23	3,		
18 (78,3%)	,		(8; 34,8%).
4 (17,3%),	3 (13,0%),		2 (8,7%)
(4,3%) .	(8,7%)		3
		(4,3%)	
			3 (13,0%)
3,	2 (8,6%)	1 (4,3%)	.
		4	,
		(50,0%)	.

Hi kvadrat Fišerov

($p > 0,05$).

34.

PH

	800000k/ml		1	2	8	0	2
			20,0%	25,0%	33,3%	0,0%	28,6%
	800000k/ml		4	16	16	4	5
			80,0%	87,5%	66,7%	100,0%	71,4%
12	800000k/ml		5	18	23	4	6
			100,0%	100,0%	95,8%	100,0%	85,7%
	800000k/ml		0	0	1	0	1
			0,0%	0,0%	4,2%	0,0%	14,3%
24	800000k/ml		2	6	10	3	2
			100,0%	100,0%	100,0%	100,0%	100,0%
	800000k/ml		0	0	0	0	0
			0,0%	0,0%	0,0%	0,0%	0,0%
48	800000k/ml		2	10	13	1	5
			100,0%	100,0%	100,0%	100,0%	100,0%
	800000k/ml		0	0	0	0	0
			0,0%	0,0%	0,0%	0,0%	0,0%
6	800000k/ml		4	18	23	4	4
			100,0%	100,0%	95,8%	100,0%	57,1%
	800000k/ml		0	0	1	0	3
			0,0%	0,0%	4,2%	0,0%	42,9%

800000 , , , 16 (66,7%)
, 4 (80,0%) , 5 (71,4%)
, 16 (66,7%)
. 12 , ,
(4,2%) (14,3%)
800000 .
, , 800000
(4,2%) 3 (42,9%) . Hi
kvadrat , ,
800000,
(χ²=16,04 p=0,007;
p<0,01).

35. ()

	SVR (n=50)	R (n=3)	NR (n=10)
Xsr	45,14	50,67	51,80
SD	11,73	11,02	10,92
Min	20,00	38,00	36,00
Max	78,00	58,00	75,00

(45,14±11,73), (50,67±11,02),
(51,80±10,92),
ukijev
(p>0,05).

36. ALT

	SVR (n=50)	R (n=3)	NR (n=10)
Xsr	78,62	111,73	81,56
SD	34,46	52,86	46,19
Min	38,70	51,80	38,70
Max	179,30	151,70	175,50

ALT (111,73±52,86 U/L),
 (78,62±34,46 U/L),
 (81,56±46,19 U/L)
 (ANOVA Tukijev : p>0,05).

37.

		ml		(n=63)
		800000 (n=15)	800000 (n=48)	
SVR		13	37	50
		86,7%	77,1%	79,4%
R		1	2	3
		6,7%	4,2%	4,8%
NR		1	9	10
		6,7%	18,8%	15,9%

800000

13 (86,7%)

2 (4,2%) , (6,7%) .
 37 (77,1%) , 800000
 9 (18,8%) .

Hi kvadrat Fišerov

($p > 0,05$).

38 .

		95% IP OR		p
	0,824	0,233	2,910	0,764
	0,953	0,902	1,007	0,086
	0,383	0,109	1,343	0,134
	0,478	0,077	2,953	0,427
	6,182	0,740	51,618	0,093
	0,000	0,000	.	0,999
	3,000	0,348	25,870	0,318
ALT	0,993	0,978	1,009	0,394
1	0,938	0,268	3,280	0,920
3	0,900	0,256	3,166	0,870
4	0,000	0,000	.	0,999
F0	0,000	0,000	.	0,999
F1	0,732	0,167	3,209	0,679
F2	1,500	0,406	5,541	0,543
F3	0,000	0,000	.	0,999
F4	0,290	0,056	1,503	0,140

($p > 0,05$).

7.

,
.
,
.
- 2018. .
.
rmstronga . (3) 20 59 .
Iwasaki . (10) 54,3 .
46,23 .
(18, 42, 51).
(52, 53, 54, 55).
66% 30-39
(31,25%).
, 28 (43,8%).
30-40%
(8, 11, 24, 26, 52, 53).
2% (54,
55).

18 (28,1%)
20-40 .
. arinho .
(56) 90%
. .
70% , 80%
() 92% .
(56, 57). ,
,
.
:
,
,
11 (17,2%)
50-70 ,
80- ,
(1994).
(54, 58, 59).
,
.
,
(59).
,

20 ,

0-12%, (1.3%)

60). , 4,4% (59,
(1.6%)

ALT, LT
58,7%

LT 25% (61). urawaki . (62)
LT LT
64). (63,

Strauber . (65) ST/ LT

ST/ LT > = 1,
(64, 66, 67, 68, 69, 70).

LT.

1, 39 (60,9%),
3, 23 (35,9%) 4, 2 (3,1%). 2, 5 6
5 6

(24) ,

1 (71, 72, 73) ,
3 (33, 74, 75, 76).
, 5

5 (15, 2%)
1 , 3
2 3 (F1
F2) 25 (75,8 %) 1 16 (69,6%)
3
4 (2)

800000k/ml, 49 (76,6%),
800000 k/ml, 15 (23,4%).
(800000k/ml)
, 34 (81,0%) ,
, 800000k/ml
, 5 (71,4%) , 4

16

1
800000k/ml 30 (76,9%),
3 ,17 (73,9%) 4

37
800000k/ml 13 800000k/ml. Yan
76

Zhu- (77) Di-Marco-a (78) SVR,

SVR

SVR

(73, 79, 80) 4

SVR (81, 82). Pattullo (83)

SVR. (61%)

SVR (39%) Lee (84).

2 3

Lacoma

(85) 40.

(F1-F2), 2, 3 4 6×10^5

UL/ml su SVR.

SVR (VR),

2 log 12

(42, 73, 79, 80, 86, 87, 88).

800000k/ml, 12 3

1.

40

(F3, F4) SVR 3,8%, ovo (89).

78,9 % 1, 78,3% 3

4. SVR 75-80%

2 3, 40-50% 1 (73, 77, 90, 92).

32 1, SVR

26 (81,3 %) (37,5%)

(28,2%), 3 (9,4%) 2

5 (1, 2 2).

23 3,

18 (78,3%). 34,8% ,

17,3%, 13,0% , 8,7%,

3 , 2 1

4

SVR

50%

(3 4) (92, 93).

Kim . (94) SVR ,

SVR 2, 3 4

, SVR (95).

im . (96) SVR

LT- , 1.

LT- ,

LT-

LT-

SVR

Uchida . (97).

(98).

(-)

(99, 100). 20% -

, Fontana . (101)

Hrsti . (102).

(boceprevir i telaprevir)

- / 1 (90).

(RVR) 56-60%

, SVR 70-80% (95, 103, 104, 105).

8.

1. 1, 3.

2. .

3.

30-50. .

4.

5. LT- .

6. , ,

. .

7.

. .

8. PH SVR .

1. Teodorovi J. i sar. Gastroenterologija. Excelsior, Beograd 1999.
2. Alter MJ. Epidemiology of hepatitis C. *Hepatology*.1997; 26 (3 Suppl 1): 62S-5S.
3. Armstrong GL, Waslay A, Simard ED et al. The prevalence of hepatitis C virus Infection in United States, 1999 through 2002. *Ann Intern Med* 2006; 144 (10): 505-14.
4. Lauer GM, Walker BD. Medical progress: Hepatitis C virus Infection. *N Engl J Med* 2001; 345(1): 41-52.
5. Jemuovic LJ. Hroni ni virusni hepatitis C. Zadužbina Andrejevi , Beograd 2000.
6. Konstantinovi Lj. Virusni hepatitis C. Prosveta, Niš 1997.
7. Deli D, Nikoli P, Boži M. Virusni hepatitis. Zavod za u benike i nastavna sredstva, Beograd 1998.
8. Higuchi M, Tanaka E, Kiyosawa K. Epidemiology and clinical aspects on hepatitis C. *Jpn J Infect Dis* 2002; 55 (3): 69-77.
9. Fabri M, Klašnja B, Ruži M, Pobor M, Praveden T. Epidemiološke karakteristike hepatitis C virusne infekcije anti –HCV pozitivnih osoba le enih u klinici za infektivne bolesti u Novom Sadu. *Acta Infectologica Yugoslavica* 2003; 8 (1): 19-24.
10. Iwasaki M, Kanda D, Toyoda M, Yuasa K, Hashimoto Y, Takagi H, Mori M, Suzuki S. Absence of specific symptoms in chronic hepatitis C. *J.Gastroenterol* 2002; 37: 709-16.
11. Esteban JI, Sauleda S, Quer J. The changing epidemyology of hepatitis C virus infection in Europe. *J Hepatol* 2007; Abstract.
12. Deli D, Neši Z, Simonovi J. Hepatitis C i ortotopi ka transplantacija jetre: problemi i rešenja. *Acta Infectologica Yugoslavica* 2003; 8 (1):49-53.
13. Alexopoulou A, Papatheodoridis GV. Current progres in the treatment of chronic hepatitis C. *World J Gastroenterol* 2012 ; 18 (42): 6060-69.
14. Casanova YS, Boeira TdaR, Sisti E, Celmer A, Foncesca AS, Ikuta N, Simon D, Lunge VR. A complete molecular biology assay for hepatitis C virus detection, quantification and genotyping. *Rev Soc Bras Med Trop* 2014; 47(3): 287-94.
15. Hrsti I, Vuceli B. Biological prosperties of hepatitis C virus. *Medicina* 2007; 43: 107-11.

16. Neškovi G, upi -Jovanovi S, Živkovi J, Spasojev –Tišma. Molekularna biologija hepatitisa C virusa. *Acta Infectologica Yugoslavica* 2003; 8 (1): 5-11.
17. Alter MJ. Epidemiology of hepatitis C virus infection. *World J Gastroenterol* 2007; 13 (17):2436-41.
18. Lauer GM, Walker BD. Medical progres: Hepatitis C virus infection *N Engl J Med.* 2001; 345 (1): 41-52.
19. Holmes J, Thomson A, Bell S. Hepatitis C update. *Aust Fam Physician* 2013; 42 (7): 452-6.
- 20 . Concensus Conference. Tretman of hepatitis C. Paris, France, 2002.
21. Haushofer AC, Kopty C, Hauer R, Brunner H, Halbmayer WM. HCV genotypes and age distribution in patients of Vienna and surrounding areas. *J Clin Virol* 2001; 20 (1-2): 41-7.
22. Chevaliez S, Pawlotsky JM. Hepatitis C virus: Virology, diagnosis and menagement of antiviral therapy. *World J Gastroenterol* 2007; 13 (17): 2461-6.
23. Wasley A, Alter MJ. Epidemiology of hepatitis C; geographic differences and temporal trends. *Semin Liver Dis* 2000; 20 (1): 1-16. Abstract
24. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. *Lancet Infect Dis* 2005; 5: 558-67.
25. Nikolaeva LI, Blokhina NP, Tsurikova NN , Veronkova NV, Miminoshvili MI, Braginsky DM, Yastrebova ON, Booyantskaya OB, Isaeva OV, Michailov Mi, Archakov AI .Virus-specific antibody titres in different phases of hepatitis C virus infection. *J Viral Hepatitis* 2002; 9 (6):429-37.
26. Alberti A, Chemello L, Benvegno L. Natural history of hepatitis C. *J Hepatol* 1999; 31 (1): 17-24.
27. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. *Hepatology* 1997; 26 (3 Suppl 1): 34S-38S.
28. Lawrence SP. Advances in the treatment of hepatitis C. *Adv Intern Med* 2000; 45: 65-105.
29. Cheng Z, Zhou B, Shi X, Zhang L, Chen L, Liu X. Extrahepatic manifestations of chronic hepatitis C virus infection: 297 cases from a tertiary medical center in Beijing, China. *Chin Med J (Engl)* 2014; 127(7):1206-10.
30. Zampino R, Marrone A, Restivo L, Guerrera B, Sellito A, Rinaldi L, Romano C, Adinolfi LE. Chronic HCV infection and inflamation: Clinical impact on hepatic and extra-hepatic manifestations. *World J Hepatol* 2013; 5 (10): 528-40.

31. Galosi A, Guarisco R, Bells L et al. Extrahepatic manifestations of chronic HCV infection. *J Gastrointest Liver Dis* 2007; 16 (1):65-73.
32. Geler SA. and Petrovic LM. Chronic hepatitis (Chronic necroinflammatory Disease of the liver) 83-97b in *Biopsy interpretation of the liver*, Lipincot Williams & Wilkins, 2004.
33. Guido M, Ruge M. Liver fibrosis: natural history may be affected by the biopsy sample. *Gut* 2004; 53 (12): 1878-81.
34. Blackard JT, Shata MT, Shire NJ, Sherman KE. Acute hepatitis C virus infection: a chronic problem. *Hepatology* 2008; 47 (1): 321-31.
35. Weigand K, Stremmel W, Eneke J. Treatment of hepatitis C virus infection. *World J Gastroenterol* 2007; 13 (13):1897-905.
36. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Claxi A, Lin A, Hoffman J, Yu J. Peginterferon Alfa -2a plus Ribavirin for Chronic Hepatitis C Virus Infection. *N Engl J Med* 2002; 347 (13): 975-82.
37. Zeuzem S, Feinman V, Rasenack J, Heathcote EJ, Lai MY, Gane E, Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa -2a in patients with chronic hepatitis C. *N Engl J Med* 2000; 343; 1666-72.
38. Carlsson T, Reichard O, Norkrans G, Blackberg J, Sangfelt P, Wallmark E, Weiland O. Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon – alfa 2a ribavirin according to virological response. *J Viral Hepatitis* 2005; 12: 473-80.
39. Gonzales V, Padilla E, Diago M et al. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha- 2a plus ribavirin. *J Viral Hepatitis* 2005; 12: 481-7.
40. Engler S, Flechtenmacher C, Wiedemann KH, Gugler R, Stremmel W, Kallinowski B. Interferon alfa 2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. *J Viral Hepatitis* 2004; 11: 60-8.
41. Portal I, Bourliere M, Halfon P. Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder- relapser hepatitis C patients: a prospective multicentre randomized controlled study. *J Viral Hepatitis* 2003; 10: 215-23.
42. Kulji - Kapulica N, Jovanovi D, Savi D, Ristanovi E, Noži D, Raji R. Terapija hroni nog hepatitis C- pra enje virusološkog odgovora. *Vojnosanit Pregl* 2010; 67 (11): 923-27.
43. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The obsvir, metavir, clinivir and dosvir groups. *Lancet* 1997; 349: 825-32.

44. Bojovi K. Klinički i terapijski značaj i koncentracije virusne nukleinske kiseline kod hepatitisa B i hepatitisa C virusne infekcije. Doktorska disertacija, Medicinski fakultet, Kosovska Mitrovica 2007.
45. Scotto G, Fazio V, Fornabio C et al. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b. *Drugs* 2008; 68 (6): 791-801.
46. Andronescu D, Diaconu S, Tiuca N, Purcarea RM, Andronescu CI. Hepatitis C treatment & management. *J Med Life* 2014; 7 (1): 31-6.
47. Fabri M, Božić M, Deli D, Jesić R, Nožić D. Treatment of chronic hepatitis C with PEG-interferon. *Med Pregl* 2003; 56 (9-10): 427-30.
48. Degasperi E, Aghemo A. Sofosbuvir for the treatment of chronic hepatitis C : between current evidence and future perspectives. *Hepat Med* 2014; 6: 25-33.
49. Ashfaq UA, Idress S. Medical plants against hepatitis C virus. *World J Gastroenterol* 2014; 20 (11): 2941-7.
50. Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations; our experience and review. *World J Gastroenterol* 2013 ;19 (47): 8940-8.
51. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. *J Hepatol* 2000; 32: 98-112.
52. Jemuović Lj, Borić I, Deli D, Nikolić P. Epidemiološke, kliničke, biohemijske i histopatološke karakteristike hroničnog hepatitisa C: prikaz 84 pacijenta. *Acta Infectologica Yugoslavica* 2001; 6: 201-10.
53. Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. *BMC Infect Dis* 2012; 12 (Suppl 2): S2.
54. Yano M, Yatsunami H, Inoue O, Inokuchi K, Koga M. Epidemiology and long term prognosis of hepatitis C virus infection in Japan. *Gut* 1993; 34: S13-S16.
55. Kleven RM, Hu DJ, Jiles R, Holmberg SD. Evolving epidemiology of hepatitis C virus in the United States. *Clin Infect Dis* 2012; 55(1): S3-9.
56. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. *World J Gastroenterol* 2013; 19 (40): 6703-9.
57. Lukačević E. Hronični hepatitis C kod intravenoznih narkomana. *Sanamed* 2011; 6(1): 9-11.

58. Lindsay KL, Rosenberg J. Hepatitis C. *West J Med* 1998; 169 (6): 372-3.
59. Terrault NA, Dodge JI, Murphy EL, Tavis JE, Kiss A, Levin TR, Gish RG, Busch MP, Reingold AL, Alter MJ. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. *Hepatology* 2013; 57 (3): 881-9. Abstrakt
60. Tohme RA and Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission. *Hepatology* 2010; 52(4): 1497-505.
61. Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, Trepo C. Predictive Value of ALT Levels for Histologic Findings in Chronic Hepatitis C: A European Collaborative Study. *Hepatology* 2002; 36: 973-7.
62. Murawaki Y, Ikuta Y, Okamoto K. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. *J Gastroenterol* 2001; 36: 399-406.
63. Kazuaki C. Management of chronic hepatitis C and prevention of hepatocellular carcinoma. *J Gastroenterol* 2002; 37: 69-73.
64. Sinn DH, Gwak GY, Shin JU et al. Disease progression in chronic hepatitis C patients with normal alanin aminotransferase levels. *World J Gastroenterol* 2013; 19 (14): 2256-61.
65. Strauber EF, Lacner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. *World J Gastroenterol* 2007; 13 (32): 4287-94.
66. Park GJ, Lin BP, Jones DB, Kateralis PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? *J Gastroenterol Hepatol* 2000; 15 (4): 386-90.
67. Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. *Am J Gastroenterol* 1998; 93: 44-8.
68. Fouad SA, Esmat S, Omran D, Rashid L, Kobaisi MH. Noninvasive assessment of hepatic fibrosis in Egyptian patients with chronic hepatitis C virus infection. *World J Gastroenterol* 2012; 18 (23): 2988-94.
69. Luka E, Gligorijevi J, Konstantinovi Lj. Serum transaminase levels and fibrose stage in zero biopsy of the lever in chronic hepatitis C. *Facta universitatis* 2007; 14(1): 19-24.
70. Luka E. Korelacija patohistoloških i biohemijskih promena u hroni nom hepatitisu C. Magistarski rad, Niš 2008.

71. Irshad M, Mankotia DS, Irshad K. An insight into the diagnosis and pathogenesis of hepatitis C virus infection. *World J Gastroenterol* 2013; 19(44): 7896-909.
72. Hajdon GH, Javis LM, Simmonds P, Harrison DJ, Garden OJ, Hayes PC. Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population. *Gut* 1997; 40: 128-32.
73. Chuang WL, Yu ML. Host factors determining the efficacy of hepatitis C treatment. *J Gastroenterol* 2013; 48: 22-30.
74. Hwang S, Lee SD. Hepatic steatosis and hepatitis C: Still Unhappy bedfellows? *J Gastroenterol Hepatol* 2011; 26: 96-101.
75. Negro F. Mechanisms and significance of liver steatosis in hepatic C virus infection. *World J Gastroenterol* 2006; 12 (42): 6756-65.
76. Yoon EJ, Hu KQ. Hepatitis C virus (HCV) infection and hepatic steatosis. *Int J Med Sci* 2006; 3 (2):53-6.
77. Yan Z, Chen S. Antiviral treatment of hepatitis C virus infection and factor affecting efficacy. *World J Gastroenterol* 2013; 19 (47): 8963-73.
78. Di Marco V, Covolo L, Calvaruso V, Levrello M, Puoti M, Sufer F, Gaeta GB; Ferrari C, Raimondo G, Fatovich G, Santantonio T, Alberti A, Bruno R, Mussini C, Mondelli M, Donato F, Craxi A. Who is more likely respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. *J Viral Hepat* 2013; 20 (11): 790-800.
79. Gatselis NK, Zachou K, Saitis A. Individualisation of chronic hepatitis C treatment according to the host characteristics. *World J Gastroenterol* 2014; 21 (11): 2839-53.
80. Izumi N, Asahina Y, Kurosaki M. Predictors of Virological Response to a Combination Therapy with Pegylated Interferon Plus Ribavirin Including Virus and Host Factors. *Hepat Res Treat* 2010; 2010: 703602.
81. Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon – and ribavirin in patients with chronic hepatitis C infection. *J Family Community Med* 2013; 20: 35-40.
82. Esmat G, El Raziku M, El Kassas M, Hassanu M, Gamil ME. The future for the treatment of genotype 4 chronic hepatitis C. *Liver Int* 2012; 1: 146-50.
83. Pattullo V, Heathcote EJ, Wong DK. Superior response to pegylated interferon and ribavirin in Asians with chronic hepatitis C. *Hepatol Int* 2010; 4 (4): 723-31.

84. Lee HS, Kweon YO, Tak WY, Park SY, Kana EJ, Lee YL, Yang HM, Park HW. Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients. *Clin Mol Hepatol* 2013; 19(2): 148-55.
85. Lacomis F, Lannicelli G, Franceschini A et al. HCV infected prisoners: should they be still considered a difficult to treat population? *BMC Infect Dis* 2013; 13:374
86. Morisco F, Granata R, Caporasa N. Sustained virological response. A milestone in the treatment of chronic hepatitis C. *World J Gastroenterol* 2013; 19 (18): 2793-98.
87. Zanini B, Benini F, Pigozzi MG, Furba P, Giaco E, Cinguegrana A, Fasoli M, Lanzini A. Addicts with chronic hepatitis C: Difficult to reach, manage or treat. *World J Gastroenterol* 2013; 19 (44): 8011-9.
88. Lin Kh, Yu HC, Hsu PI, Tsai WL, Chen WC, Lin CK, Chan HH, Tsay FW, Lai KH. Baseline high viral load and unfavorable pattern of alanine aminotransferase change predict virological relapse in patients with chronic hepatitis C genotype 1 or 2 obtaining rapid virological response during antiviral therapy. *Hepat Mon* 2013; 13 (10): e11892.
89. Tovo CV, De Mattos AA, De Almeida PBL. Chronic hepatitis C genotype 1 virus: Who should wait for treatment? *World J Gastroenterol* 2014; 20 (11): 2867-75.
90. Ahn J, Flamm SL. Frontiers in the treatment of hepatitis C virus infection. *Gastroenterol Hepatol* 2014; 10 (2): 90-100.
91. Grassi E, Aghemo A. How to optimize HCV therapy in genotype 2 patients. *Liver Int* 2013;1: 35-40.
92. Marcellin P, Bourliere M, Pawlotsky JM, Ouzan D. HCV non-responder patients: definition of non-response and treatment strategy 2007; 31: 4S13-9.
93. Poynard T, Moussali J, Ratziu V, Regimbeau C, Opolon P. Effects of interferon therapy in „ non responder” patients with chronic hepatitis C. *J Hepatol* 1999; 1: 178-83.
94. Kim KH, Jang BK, Chung WJ, Hwang JS, Kweon YO, Tak WJ, Lee HJ, Suh JI. Peginterferon alfa and ribavirin combination therapy in patients with hepatitis C virus –related liver cirrhosis. *Korean J Hepatol* 2011; 17(3): 220-5.
95. Bourliere M, Khaloun A, Wartelle-Bladou C, Oules V, Portal I, Beneli S, Adhoute X, Castellani P. Future treatment of patients with HCV cirrhosis. *Liver Int* 2012; 1: 113-9.
96. Kim YJ, Jang BK, Kim ES, Park KS, Cho KB, Chung WJ, Hwang JS. Rapid normalisation of alanine aminotransferase predicts viral response during combined peginterferon and ribavirin treatment in chronic hepatitis C patients. *Korean J Hepatol* 2012; 18:41-7.

97. Uchida T, Taira M, Shicata T, Moriyama M, Tanaka N, Okubo H, Arakawa Y. Histological difference between complete responders and non-responders to interferon therapy of the livers of patients with chronic hepatitis C. *Acta Pathol Jpn* 1993; 43 (5): 230-6.
98. Ghang MG, Kleiner DE, Alter H, Promrat K, Herion D, Park Y, Liang TJ, Hoofnagle JH. Progresion of fibrosis in chronic hepatitis. *Gastroenterology* 2003; 124: 97-104.
99. Heathcote J. Retreatment of chronic hepatitis C: who and how? *Liver Int* 2009; 1: 49-56.
100. Stern C, Martinol-Peignoux M, Ripault MP, Boyer N, Castelnay C, Valla D, Marcellin P. Impact of ribavirin dose on retreatment of chronic hepatitis C patients. *World J Gastroenterol* 2012; 18 (23): 2966-72.
101. Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. *Clin Gastroenterol Hepatol* 2009; 7 (2): 219-26.
102. Hrsti I, Ostoji R, Vuceli B. Retreatment options for patients with chronic hepatitis C. *Acta Med Croatica* 2009; 63 (5): 417-22.
103. Shiffman ML, Esteban R. Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir? *Liver Int* 2012; 32: 54-60.
104. Shiffman ML, Benhamou Y. HCV F1/F2 patients: treat now or continue to wait. *Liver Int* 2014; 34: 79-84.
105. Manglia A, Mottola. What's new in HCV genotype 2 treatment. *Liver Int* 2012; 32: 135-40.

ИНДЕТИФИКАЦИОНА СТРАНИЦА ДОКТОРСКЕ ДИСЕРТАЦИЈЕ

<i>I. Аутор</i>
Име и презиме: Елвира Лукач-Радончић
Датум и место рођења: 02.09.1970. Нови Пазар
Садашње запослење: Дом здравља Нови Пазар
<i>II. Докторска дисертација</i>
Наслов: Компарација успеха антивирусне терапије у односу на фазу развоја хепатитиса Ц вирусне инфекције
Број страница: 89
Број слика:3
Број библиографских података:105
Установа и место где је рад израђен: Инфективна клиника КБЦ Крагујевац
Научна област (УДК): Инфективне болести
Ментор: Проф. др Радослав Катанић
<i>III. Оцена и одбрана</i>
Датум пријаве теме: 23.05.2011.год.
Број одлуке и датум прихватања докторске дисертације: 05-1483 , 07.12.2011.год.
Комисија за оцену подобности теме и кандидата: Проф. др Радослав Катанић Проф. др Љиљана Константиновић Проф. др Наташа Катанић
Комисија за оцену докторске дисертације: Проф. др Радослав Катанић Проф. др Драган Микић Проф. др Наташа Катанић
Комисија за одбрану докторске дисертације: Проф. др Радослав Катанић Проф. др Драган Микић Проф. др Наташа Катанић
Датум одбране дисертације: 27.11.2014.год.